NCT04963153 2026-05-13Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and ImmunotherapyNational Cancer Institute (NCI)Phase 1 Active not recruiting24 enrolled